

---

primary studies - published RCT

## **Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study.**

**Code:** PM41138737

**Year:** 2026 **Date:** 1989

**Author:** Sermet-Gaudelus I

### **Study design (if review, criteria of inclusion for studies)**

randomised crossover trial

### **Interventions**

The number of capsules of Cotazym-S-Forte (10,000 BP units of lipase activity per capsule) administered was half the usual number of Pancrease capsules (5000 BP units lipase per capsule)

### **Outcome measures**

fat absorption

### **Main results**

Cotazym-S-Fortewas associated with the same degree of fat absorption as Pancrease.

[http://dx.doi.org/10.1016/S2213-2600\(25\)00248-6](http://dx.doi.org/10.1016/S2213-2600(25)00248-6)

### **See also**

Lancet Respir Med. 2026 Jan;14(1):38-48. doi: 10.1016/S2213-2600(25)00248-6. Epub 2025 Oct 22.

### **Keywords**

Adolescent; Child; Delayed-Action Preparations; Drug Administration Schedule; Infant; pharmacological\_intervention; Pancreatic Enzyme Replacement Therapy; Supplementation; Pancreas insufficiency; Pancreatic Diseases; Gastrointestinal Diseases; Malabsorption; Nutrition Disorders; Capsules; Gastrointestinal Agents;